The Leukemia & Lymphoma Society has awarded a $971,484 Screen to Lead grant to University of North Carolina Lineberger Comprehensive Cancer Center researchers to launch an investigation of new drug compounds that would block enzymes that can become hyperactive in blood cancer cells when mutated. UNC Lineberger’s John Sondek, PhD, a professor in the UNC … Continued
Etteinne “ET” and W. G. Champion “Champ” Mitchell of New Bern, North Carolina, will create a new fund supporting ground-breaking research in blood cancer at UNC Lineberger Comprehensive Cancer Center, including lymphoma, leukemia and myeloma research, in gratitude for the care Champ received and to bolster research directed at finding cures.
UNC Lineberger, with its U.S. FDA-approved Good Manufacturing Practices, or “clean,” facility, is one of only a select academic centers in the United States with the capability to genetically modify patient immune cells for clinical use. This makes it possible for people who live in the Southeastern U.S. to stay closer to home to undergo cellular immunotherapy treatment.
UNC Lineberger researcher Ben Major, PhD, an assistant professor in the UNC School of Medicine Department of Cell Biology and Physiology, studies cell signaling pathways in normal and cancerous cells. He hopes that a finding made by his team earlier this year could lead to a new treatment for a typically fast-growing type of lymphoma.